EUVIMEDEUVIMED entdecken
Crossref

Leptomeningeal Metastasis in Patients With EGFR-positive NSCLC: A Propensity-matched Retrospective Study of Patients With EGFR-negative NSCLC

Hiroaki Satoh, Kunihiko Miyazaki, Ryota Nakamura, Ayumi Watanabe, Yosuke Maezawa, Gen Ohara, Norihiro Kikuchi, Toshihiro Shiozawa

Anticancer Research · 2026

DOI: 10.21873/anticanres.18063 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Anticancer Research, 2026. Verfasst von Hiroaki Satoh und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Respiratory Medicine, Mito Medical Center, University of Tsukuba-Mito Kyodo General Hospital, Mito, Japan; hirosato@md.tsukuba.ac.jp. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Meningeal Carcinomatosis, Meningeal Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND/AIM: Although patients with epidermal growth factor receptor (EGFR)-positive non-small cell lung cancer (NSCLC) can expect long-term survival, some patients develop leptomeningeal metastasis (LM). The study aimed to clarify whether patients with EGFR-positive NSCLC have a higher incidence of LM than patients with EGFR-negative NSCLC using propensity matching, and to clarify the clinical characteristics of patients with EGFR-positive NSCLC who develop LM. PATIENTS AND METHODS: This retrospective study reviewed the medical records of consecutive patients diagnosed with NSCLC from 2009 to 2025. In addition to common non-parametric tests, we performed propensity matching. RESULTS: We evaluated 895 patients with NSCLC, including 185 EGFR-positive patients. The incidence of LM was higher in EGFR-positive patients than in EGFR-negative patients (2.7% vs. 1.4%; p=0.01). Using propensity matching for age, sex, pathological type, and clinical stage, we confirmed the incidence of LM in EGFR-positive patients was higher than in EGFR-negative patients (9.1% vs. 1.2%; p=0.01). In EGFR-positive patients, LM was more likely to develop in younger women, and in those with brain or bone metastases, or pleural or peritoneal dissemination during their clinical courses. Among patients with LM, EGFR-positive patients had a longer time from LM onset to death. Among EGFR-positive patients who developed LM, those who received osimertinib tended to have a longer time to onset of LM and a longer overall survival. CONCLUSION: LM has been attracting attention, possibly due to the long-term survival achieved by EGFR-tyrosine kinase inhibitors. Additional information is required to clarify the risk of LM.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsMeningeal CarcinomatosisMeningeal NeoplasmsHumansFemaleErbB ReceptorsMaleRetrospective StudiesAgedMiddle AgedPropensity ScoreAged, 80 and overProtein Kinase InhibitorsPyrimidinesIndolesIncidenceAniline CompoundsAcrylamidesAdult

Stichwörter der Autor:innen

Epidermal growth factor receptorleptomeningeal metastasisnon-small cell lung cancerpropensity matchingtyrosine kinase inhibitor

Substanzen

ErbB ReceptorsEGFR protein, humanProtein Kinase InhibitorsPyrimidinesIndolesAniline CompoundsAcrylamidesosimertinib

Autor:innen und Institutionen

  • Division of Respiratory Medicine, Mito Medical Center, University of Tsukuba-Mito Kyodo General Hospital, Mito, Japan; hirosato@md.tsukuba.ac.jp.
  • Division of Respiratory Medicine, Ryugasaki Saiseikai Hospital, Ryugasaki, Japan.
  • Department of Surgery, National Hospital Organization Mito Medical Center, Mito, Japan.
  • Division of Respiratory Medicine, Kasumigaura Medical Center, University of Tsukuba-Kasumigaura Medical Center Hospital, Tsuchiura, Japan.
  • Division of Respiratory Medicine, Mito Medical Center, University of Tsukuba-Mito Kyodo General Hospital, Mito, Japan.
  • Division of Respiratory Medicine, Faculty of Clinical Medicine, University of Tsukuba, Tsukuba, Japan.

Zitieren

APA

Satoh, H., Miyazaki, K., Nakamura, R., Watanabe, A., Maezawa, Y., Ohara, G., Kikuchi, N., & Shiozawa, T. (2026). Leptomeningeal Metastasis in Patients With EGFR-positive NSCLC: A Propensity-matched Retrospective Study of Patients With EGFR-negative NSCLC. Anticancer Research. https://doi.org/10.21873/anticanres.18063

Vancouver

Satoh H, Miyazaki K, Nakamura R, Watanabe A, Maezawa Y, Ohara G, et al. Leptomeningeal Metastasis in Patients With EGFR-positive NSCLC: A Propensity-matched Retrospective Study of Patients With EGFR-negative NSCLC. Anticancer Research. 2026. doi:10.21873/anticanres.18063

BibTeX
@article{Satoh2026,
  author = {Satoh, Hiroaki and Miyazaki, Kunihiko and Nakamura, Ryota and Watanabe, Ayumi and Maezawa, Yosuke and Ohara, Gen and Kikuchi, Norihiro and Shiozawa, Toshihiro},
  title = {Leptomeningeal Metastasis in Patients With EGFR-positive NSCLC: A Propensity-matched Retrospective Study of Patients With EGFR-negative NSCLC},
  journal = {Anticancer Research},
  year = {2026},
  doi = {10.21873/anticanres.18063}
}
Kostenlos starten →